This article provides an overview of the key components of strategic plans, some best practices and biases to avoid. A winning process that includes the right people engaged in vigorous debate, avoiding biases, and making tough choices together with on-going monitoring of the environment to course correct, if necessary, will keep you focused on a winning strategic path.

Globally, over 60% of pharmaceutical industry growth can be attributed to specialty care brands. Pangaea recently interviewed a cross-range of executives in specialty and primary care pharmaceutical markets to understand how this market differs from primary care, what it takes to be successful and how the HR function can help ensure that success.

In their simplest form, SEBs are biologics — drugs created by bio- logical processes — with a demonstrated similarity to a previously approved biologic drug. Read more to find out how the regulatory environment and commercial models are unfolding and what impact is expected on the biologic market.

Quebec is undergoing its own transformation. This article highlights the changes and the implications for pharmaceuticals.

We conducted research with 22 senior executives from 12 companies on the role of emotional intelligence (EI) in the Canadian research and development pharmaceutical industry, and the results were eye opening! We concluded there is a real risk that many companies are missing the boat on a genuine opportunity to gain a competitive edge.

When we were initially approached by Astellas, they had a specific problem: Managing their relationships with retailers and distributors.

Our dedicated team of trade relations specialists helped augment Astella’s marketing team and provide hands-on assistance.